

HTANGEL

Keeping you up-to-date on
HTA decisions

Issue 40: August 2026

Dostarlimab and finerenone shine as August HTA decisions split across major therapies.

This newsletter summarises final decisions from NICE, SMC, HAS & IQWiG from published reports in August 2026.

Good news

Acalabrutinib, approved for mantle cell lymphoma and chronic lymphocytic leukaemia in England; **Dostarlimab**, approved for endometrial cancer in England and Scotland, and **Finerenone**, approved for chronic heart failure in England and Germany.

Mixed news

Zolbetuximab, approved for PD-L1 negative but not for PD-L1-positive stomach or gastroesophageal junction cancer in Germany.

Bad news

Brensocatib, with a terminated submission for non-cystic fibrosis bronchiectasis in England; **Dupilumab**, not approved for chronic spontaneous urticaria in children or in adolescents and adults in Germany; and **Teplizumab**, not approved for stage 2 diabetes mellitus type 1 in Germany.

Approvals

18

Non-approvals

15

HTANGEL

Issue 40: August 2026

Pharmacological Technologies



England
NICE TA1187

Blood
Thrombocytopenia
RILZABRUTINIB



Scotland
SMC2953

Cancer
Endometrial cancer
DOSTARLIMAB



Germany
IQWiG A26-81

Cancer
Acute myeloid
leukaemia
IVOSIDENIB



England
NICE TA1189

Cancer
Endometrial cancer
DOSTARLIMAB



Germany
IQWiG A26-83

Cancer
Breast cancer
ABEMACICLIB



England
NICE TA1186

Cancer
Follicular lymphoma
LISOCABTAGENE
MARALEUCEL



England
NICE TA1185

Cancer
Chronic lymphocytic
leukaemia
ACALABRUTINIB WITH
VENETOCLAX WITH OR
WITHOUT OBINUTUZUMAB



England
NICE TA1184

Cancer
Mantle cell lymphoma
ACALABRUTINIB WITH
BENDAMUSTINE AND
RITUXIMAB



HTANGEL

Issue 40: August 2026

Pharmacological Technologies



Scotland
SMC2967

Cancer
Neuroendocrine
cancer
CABOZANTINIB

✓ Approved



Scotland
SMC2966

Cancer
Prostate cancer
LUTETIUM VIPIVOTIDE
TETRAXETAN

⚠ Terminated



Germany
IQWiG A26-52

Cancer
Stomach cancer,
Gastroesophageal junction
cancer
ZOLBETUXIMAB

✓ Approved



Germany
IQWiG A26-52

Cancer
Stomach cancer,
Gastroesophageal junction
cancer
ZOLBETUXIMAB

✗ Not
approved



Scotland
SMC2879

Cardiovascular
Giant cell arteritis
UPADACITINIB

✓ Approved
with special
conditions



England
NICE TA1182

Cardiovascular
Heart failure
FINERENONE

✓ Approved



Germany
IQWiG A26-42

Cardiovascular
Heart failure
FINERENONE

✓ Approved



England
NICE TA1183

Cardiovascular
Hereditary
angioedema
DONIDALORSEN

✓ Approved



HTANGEL

Issue 40: August 2026

Pharmacological Technologies



Germany
IQWiG A26-82

Cardiovascular
Myocardial infarction
COLCHICINE



Germany
IQWiG A26-80

Eye
Endocrine
orbitopathy
TEPROTUMUMAB



Germany
IQWiG A26-75

Cardiovascular
Pulmonary arterial
hypertension
SOTATERCEPT



England
NICE TA1087

Eye, Respiratory
Allergic rhinitis, Allergic
conjunctivitis
12 SQ-BET SLIT



Germany
IQWiG A26-73

Endocrine
Diabetes mellitus
type 1
TEPLIZUMAB



Germany
IQWiG A26-48

Genetic & Metabolic
Acid sphingomyelase
deficiency
OLIPUDASE ALFA



Scotland
SMC2965

Endocrine
Menopause
ELINZANETANT



Scotland
SMC2884

Genetic & Metabolic
Hyperkalemia
SODIUM ZIRCONIUM
CYCLOSILICATE



HTANGEL

Issue 40: August 2026

Pharmacological Technologies



Scotland
SMC2964

Neurology

Chronic inflammatory
demyelinating
polyneuropathy

EFGARTIGIMOD ALFA



Terminated



England
NICE TA1188

Respiratory

Bronchiectasis
BRENSOCATIB



Terminated



Scotland
SMC2955

Neurology

Myasthenia gravis
ZILUCOPLAN



Approved
with special
conditions



Scotland
SMC2885

Respiratory

House dust mite allergic
rhinitis

DERMATOPHAGOIDES
PTERONYSSINUS AND
DERMATOPHAGOIDES FARINAE



Approved




Germany
IQWiG A26-76

Neurology

Neurofibromatosis
SELUMETINIB



Not
approved



Germany
IQWiG A26-49

Skin

Chronic spontaneous
urticaria
DUPILUMAB



Not
approved




Scotland
SMC2876

Neurology

Parkinson's disease
LEVODOPA, CARBIDOPA
AND ENTACAPONE



Approved



Germany
IQWiG A26-50

Skin

Chronic spontaneous
urticaria
DUPILUMAB



Not
approved



HTANGEL

Issue 40: August 2026

Diagnostic Testing



Germany
IQWiG D25-01

Eye
Diabetic retinopathy
FUNDUS
PHOTOGRAPHY




HTANGEL

Issue 40: August 2026

Further Information

HTAngel is designed to help keep you up to date with the latest HTA decisions from NICE, SMC, HAS & IQWiG specifically for pharmacological technologies and diagnostic tests.

Below is a breakdown of the tiles in the newsletter.



At Crystallise we aim to provide an innovative approach to processing information, using software tools to automate processes that are slower and less accurate when done by humans. Our approach provides clients with greater transparency and scope than they could find for the same budget elsewhere. We work with a network of experts and organisations that help us support clients efficiently and effectively, and are proud of our flexible and ingenious way of solving their problems.

For further information about HTAngel contact
newsletter@crystallise.com

To speak to us about our services contact
contact@crystallise.com

